News | Stents | June 30, 2021

FDA Clears Xience Stent for One Month DAPT in High Risk Bleeding Patients

New labeling allows for one-month dual anti-platelet therapy, FDA clears Xience Skypoint stent

Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.

Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.
 

June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug Administration (FDA) approval for one-month (as short as 28 days) dual antiplatelet therapy (DAPT) labeling for high bleeding risk (HBR) patients in the U.S. In addition, Xience stents recently received European CE mark approval for DAPT as short as 28 days, giving Xience stents the shortest DAPT indication in the world.

In addition to the HBR indication, Abbott has also received FDA approval and European CE mark approval for its next-generation Xience Skypoint stent. Xience Skypoint is easier to place and allows physicians to treat larger blood vessels through improved stent expansion that can open clogged vessels more effectively.

"The new FDA approval for DAPT for the Xience family of stents provides interventional cardiologists confidence they are delivering the best care to patients with high bleeding risk.  A short DAPT duration minimizes risks for high bleeding risk patients and allows them to return to daily life sooner and with more assurance," said Roxana Mehran, M.D., professor of medicine and director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute at Icahn School of Medicine at Mount Sinai and the global principal investigator for Abbott's Short DAPT program (XIENCE 28 and XIENCE 90).

Stents are a critical therapy option to open blood vessels that have been clogged by calcium or fatty deposits. Following stent implantation, DAPT is routinely prescribed to help prevent thrombosis, which can block a blood vessel and potentially result in heart attack or death. However, DAPT can also increase the risk of bleeding complications in some patients.[1] In fact, of all patients undergoing stenting procedures, approximately one in five are considered at high risk for bleeding.[2] 

Patients who receive stents are typically on DAPT regimens (aspirin and P2Y12 inhibitors) for six to 12 months to prevent blood clots from blocking the stented vessel. However, HBR patients can experience side effects such as bleeding during prolonged courses of DAPT. With the shortest approved DAPT labeling, Abbott's Xience stents can help physicians treat their HBR patients more effectively. Abbott's XIENCE 28 and XIENCE 90 [3] studies show that DAPT can be safely discontinued early as short as 28 days with no increased risk in patient adverse events, solidifying the industry-leading safety profile of the Xience family of stents.

FDA Clears Xience Skypoint Stent

Xience Skypoint, the latest in a line of Xience stents, is now approved for use in HBR patients with one-month DAPT labeling – as short as 28 days – in the U.S. and in Europe. Supported by 10 years of clinical data, including 120 clinical trials studying 125,000 patients and the implantation of 15 million stents, Xience drug-eluting stents (DES) have been proven safe and effective, consistently delivering successful patient outcomes.

"Even small differences between stents can impact both short- and long-term patient outcomes, and this latest generation of the Xience stent offers multiple improvements that provide enhanced deliverability and expansion capability," said Nick West, M.D., chief medical officer and divisional vice president of global medical affairs at Abbott's vascular business. "As we continue to innovate at Abbott, we are delivering medical technology that improves patients' lives, while building a body of research evidence that underlines clinical consistency and patient safety."

Xience is supported by the largest body of DAPT patient evidence, with over 24,000 patients analyzed.[4-12] Abbott continues to focus on further improving the class-leading Xience stent platform through innovation, supported by clinical data from the most complex patient populations, including HBR, with the aim of driving optimal care for patients suffering from coronary heart disease. Xience stents have more than 10 years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent implants.[13]

Important Safety Information: Xience Drug-Eluting Stents

For more information: www.abbott.com

 

Find more stent technology news

References:

1. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774–82.

2. Shanmugam VB, Harper R, Meredith I, Malaiapan Y, Psaltis PJ. An overview of PCI in the very elderly. J Geriatr Cardiol 2015;174−184.

3. https://www.cardiovascular.abbott/int/en/hcp/products/percutaneous-coronary-intervention/xience-family/xience-trial-results.html 

4. Généreux P, et al. Circ Cardiovasc Interv. 2015;8(5):1-16

5. Natsuaki et al., Cardiovasc Interv and Ther. 2016. 31:196–209.

6. Watanabe H, et al. JAMA. 2019;321(24):2414-2427.

7. Hahn J, et al. ACC 2019. SMART CHOICE. JAMA. 2019 Jun 25;321(24):2428-2437. doi: 10.1001/jama.2019.8146. 

8. Valgimigli M, et al. Circulation. 2012;125:2015-2026

9. Gilard M, et al. J Am Coll Cardiol 2015;65:777-786.

10. Hong SJ, et al. J Am Coll Cardiol Intv. 2016;9:1438–1446.

11. Gwon HC, et al. ACC 2011 - EXCELLENT.

12. Mehran R, et al. TCT Connect 2020. XIENCE 28/90.

13. https://www.cardiovascular.abbott/us/en/hcp/products/percutaneous-coronary-intervention/xience-family.html

Related Content

One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 
News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual...
The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart at
The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images

News | Antiplatelet and Anticoagulation Therapies | May 15, 2021
May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in pat
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term,...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal a
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce